You are here

  • Home
  • Archive
  • Volume 82, Issue 4
  • Response to: ‘Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’’ by Zheng

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’’ by Zheng
  1. Shahab Abtahi1,2,3,
  2. Johanna H M Driessen1,2,3,4,
  3. Andrea M Burden1,5,
  4. Patrick C Souverein2,
  5. Joop P van den Bergh6,7,8,
  6. Tjeerd P van Staa2,9,
  7. Annelies Boonen6,10,
  8. Frank de Vries1,2,3,11
  1. 1 Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands
  2. 2 Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
  3. 3 Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands
  4. 4 NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, The Netherlands
  5. 5 Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH-Zurich, Zurich, Switzerland
  6. 6 Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands
  7. 7 Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
  8. 8 Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands
  9. 9 Centre for Health Informatics, Division of Informatics, Imaging and Data Science, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
  10. 10 Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
  11. 11 MRC Epidemiology Lifecourse Unit, Southampton General Hospital, Southampton, UK
  1. Correspondence to Prof Frank de Vries, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO BOX 80082, 3508 TB, Utrecht, The Netherlands; f.devries{at}uu.nl

http://dx.doi.org/10.1136/annrheumdis-2021-219856

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Zheng for his comments on our recently published article in the Annals of the Rheumatic Diseases entitled ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’.1 2 Our main goal in this study was to bring more clinical insight into the simultaneous use of these two common medications in patients with rheumatoid arthritis (RA), that is, oral glucocorticoids (GCs) and proton pump inhibitors (PPIs), using data from a large primary care database and pharmacoepidemiological methodologies.

    Our results showed that there was an interaction in the risk of osteoporotic (OP) fractures with concomitant use of oral GCs and PPIs in patients with RA. Based on the adjusted hazard …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Twitter @Sh_Abtahi, @ETH_PharmEpi

    • Correction notice This article has been corrected since it published Online First. Reference 3 has been corrected.

    • Contributors SA and JD conducted the data analysis. All authors contributed to data interpretation. SA wrote the manuscript. All authors were involved in editing or quality control. All authors are accountable for their own contribution, in addition to all aspects of the manuscript. All authors have approved the submitted version of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests JvdB reports grants from Amgen, Eli Lilly and UCB, outside the submitted work. AB received research grants to her department from Celgene and AbbVie, and speakers’ fees or honoraria from Sandoz, UCB, Lilly, Novartis and Biogen, and Gilead also to her department, not related to the current study. FdV supervises 3 PhD students who are employed with F. Hoffmann La Roche Ltd (Basel, Switzerland/Welwyn Garden City, UK). He has not received any fees or reimbursements for this, and the topics of their PhD thesis are not related to the current study proposal. SA, JD, AMB, PCS and TPvS have no competing interests.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles